RWE and Patient-Centered Outcomes
Widespread availability of real-world data has enabled the generation of evidence and insights that benefit patients, providers, plans, and industry. When that evidence reflects patient outcomes, it provides an invaluable perspective on the consumer experience. Explore our real-world evidence (RWE) analyses and guidance to support your strategic decisions.
White Paper: The Cost of Opioid Use Disorder
Avalere Health finds opioid use disorder costs businesses, governments, and households almost $1 trillion per year, but treatment with medications can lower costs.
RWE Data Management Lessons Applicable to NIH Autism Database
The NIH recently announced plans to develop an RWE database to study autism spectrum disorders. In doing so, they can learn lessons encountered by life sciences companies developing data ecosystems for their products.
Manufacturers Must Adapt to Growing GLP-1 and GIP/GLP-1 RA Markets
As the GLP-1 product market continues to expand, manufacturers must find ways to differentiate their inline and pipeline assets with new evidence and strong value story.
National Kidney Month: Setting the Stage for 2025 Changes
Political changes, transplant system reforms, research advancements, and expanded CKD indications create opportunities and challenges in the kidney care space.
Disease Registries Offer Solutions in Rare Disease
Disease registries can provide high-quality data and may serve as an additional resource when developing medical interventions for rare and ultra-rare diseases.
Telehealth in Medicare: Shifts Before and After COVID-19
Pandemic-era telehealth flexibilities in Medicare will expire in April 2025, potentially limiting primary care access for beneficiaries.
Stakeholders Can Influence Patient-Centered Value Research During Public Comment Period
Life sciences companies, payers, and advocates can weigh in on patient-centered value assessments in a new public comment opportunity.
Opportunities to Move the Needle on US Behavioral Healthcare in 2025
Behavioral health is at a turning point in 2025, with newly implemented policies, groundbreaking treatments, and novel regulatory and financial dynamics.
eBook: Rare Disease Biotechnology Landscape
In an eBook, Avalere Health experts describe the policy, market access, and evidence landscape of rare disease in the United States and globally.
Evidence Generation and Access at the San Antonio Breast Cancer Symposium
At a breast cancer symposium, Avalere oncology advisory experts connected with colleagues to discuss early detection, precision medicine, and clinical trials.
NORD Summit Reveals 2025 Rare Disease Priorities
Avalere attendees of the National Organization of Rare Disorders (NORD) Breakthrough Summit shared a recap of themes from the conference in MedAd News.
Avalere Published in PM360: Research that Reflects Reality
For researchers developing new medicines and therapies, real-world data gives them an understanding of patients’ actual experiences outside of clinical trials.
Rethinking Evidence Strategy in HEOR Budget Planning
Avalere experts in health economics and outcomes research (HEOR) identify four elements of evidence strategy development in Pharma Focus America.
Updated Negotiation ICR Presents New Industry Evidence Needs
Updates in the Initial IPAY 2027 ICR highlight the increasing needs for specific evidence planning and generation for industry to prepare for negotiation.
Rethink Evidence Strategy this HEOR Budget Planning Season
Budgeting season offers HEOR teams the opportunity to revisit research and evidence needs and update their commercialization strategy based on market dynamics.
Mental Health Treatment Integration Can Offer Cost Savings
Adequately treating mental health disorders can cut overall costs, including those from comorbidities, despite access barriers and high comorbidity expenses.
Establishing Value in an Uncertain and Dynamic Landscape
On June 5, The Evidence Base published an article entitled, “Navigating uncertainty: redefining healthcare value in an evolving healthcare landscape,” covering key topics from Avalere’s ISPOR theater session.
Five Data Strategy Questions Pharma Should Ask For 2025
When utilizing and acquiring data, life sciences companies should consider these top questions and key implications for their 2024–2025 strategic plans.
CMMI Quality Pathway Prioritizes Patient-Centered Value
Innovation models will prioritize improving quality and redefine how quality is measured.
Video: Discussing Value at Asembia and ISPOR
Ahead of the upcoming Asembia and ISPOR conferences, Avalere experts discuss the role of external assessors in value assessment.